Holen Sie sich die Stockscreener-App
1.20
15.49%
-0.22
Handel nachbörslich:
1.20
Estrella Immunopharma Inc Aktie (ESLA) Neueste Nachrichten
Is Estrella Immunopharma Inc. stock a good choice for value investors2025 Dividend Review & Fast Gain Swing Alerts - ulpravda.ru
How Estrella Immunopharma Inc. stock trades during market volatilityWeekly Trend Recap & Safe Entry Trade Reports - ulpravda.ru
How risky is Estrella Immunopharma Inc. stock nowPortfolio Value Summary & Technical Buy Zone Confirmations - ulpravda.ru
Estrella Immunopharma, Inc.Warrant (NQ: ESLAW - FinancialContent
Is Estrella Immunopharma Inc. stock a smart buy before Fed meetingWeekly Volume Report & Long-Term Growth Stock Strategies - ulpravda.ru
Can Estrella Immunopharma Inc. stock sustain market leadershipWatch List & Short-Term Trading Alerts - ulpravda.ru
Is Estrella Immunopharma Inc. stock attractive for passive investors2025 Geopolitical Influence & Accurate Intraday Trading Signals - ulpravda.ru
Published on: 2026-01-07 23:18:22 - ulpravda.ru
How interest rate cuts could boost Estrella Immunopharma Inc. stockSector Leadership Analysis & Small Capital Trading Growth - ulpravda.ru
Estrella Immunopharma Secures $8 Million in Funding to Advance Cancer Therapy Programs - citybuzz -
Estrella Immunopharma completes $8M direct offering financing - TipRanks
Estrella Immunopharma Signs Multiple Material Agreements - TradingView — Track All Markets
Estrella Immunopharma closes $8 million registered direct offering - Investing.com
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement - The AI Journal
Estrella Immunopharma closes $8 million registered direct offering By Investing.com - Investing.com India
Estrella Immunopharma raises $8 million through registered offering By Investing.com - Investing.com Nigeria
Estrella Immunopharma stock falls after announcing $8 million offering - Investing.com India
Estrella Immunopharma raises $8 million through registered offering - Investing.com
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - The AI Journal
Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Grows By 28.5% - MarketBeat
Aug Levels: How Estrella Immunopharma Inc stock reacts to global recession fearsMarket Performance Recap & Low Drawdown Momentum Trade Ideas - moha.gov.vn
Estrella Immunopharma (ESLAW) Stock Analysis Report | Financials & Insights - Benzinga
Estrella Immunopharma shares gain as CD19 cancer therapy progresses into phase II - MSN
Estrella Immunopharma offers up to 2.5 mln shares for resale by selling stockholders - marketscreener.com
Estrella Immunopharma Files for Secondary Offering - marketscreener.com
Investment Review: How interest rate cuts could boost Estrella Immunopharma Inc. stock2025 AllTime Highs & Free Growth Oriented Trading Recommendations - Улправда
Why Estrella Immunopharma Inc. stock remains on buy listsVolume Spike & Free Technical Pattern Based Buy Signals - Улправда
Is Estrella Immunopharma Inc. stock affected by interest rate hikes - Улправда
Is Estrella Immunopharma Inc. stock a safe haven assetEarnings Recap Report & Accurate Buy Signal Alerts - Улправда
Insider Buy: Is Estrella Immunopharma Inc. stock a safe haven asset2025 Breakouts & Breakdowns & High Conviction Buy Zone Picks - Улправда
Estrella Immunopharma (NASDAQ:ESLA) Trading 1.3% HigherHere's Why - MarketBeat
Levels Update: How interest rate cuts could boost Estrella Immunopharma Inc. stockWeekly Stock Recap & Verified Swing Trading Watchlists - ulpravda.ru
Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast - Defense World
Estrella Immunopharma advances STARLIGHT-1 trial after DSMB review - MSN
Estrella Immunopharma secures $3.35M in financing to advance clinical triall; shares up - MSN
Estrella Immunopharma (ESLA) Stock Analysis Report | Financials & Insights - Benzinga
Estrella’s EB103 advances to Phase II after positive safety data By Investing.com - Investing.com Nigeria
Estrella Immunopharma Advances STARLIGHT-1 Trial to Phase II - TradingView — Track All Markets
Estrella Immunopharma stock rises as cancer therapy advances to Phase II - Investing.com Canada
Estrella’s EB103 advances to Phase II after positive safety data - Investing.com
Estrella advances Starlight-1 trial into phase II following positive DSMB recommendation - marketscreener.com
Estrella (NASDAQ: ESLA) passes DSMB; EB103 high-dose cohort reports 100% CR - Stock Titan
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation - Business Wire
Is Estrella Immunopharma Inc. stock a defensive play in 2025Portfolio Gains Summary & Daily Growth Stock Investment Tips - Newser
Here's Why We're Not Too Worried About Estrella Immunopharma's (NASDAQ:ESLA) Cash Burn Situation - Sahm
Estrella Immunopharma (NASDAQ:ESLA) Raised to “Hold” at Wall Street Zen - Defense World
Estrella Immunopharma (NASDAQ:ESLA) Raised to "Hold" at Wall Street Zen - MarketBeat
How Estrella Immunopharma Inc. stock benefits from global expansionInsider Buying & Free Technical Pattern Based Buy Signals - newser.com
Published on: 2025-11-19 23:49:15 - newser.com
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):